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Abstract
Background: Since the introduction of HAART the incidence of HIV dementia has declined and
HAART seems to improve neurocognitive function in patients with HIV dementia. Currently, HIV
dementia develops mainly in patients without effective treatment, though it has also been described
in patients on HAART and milder HIV-associated neuropsychological impairment is still frequent
among HIV-1 infected patients regardless of HAART. Elevated cerebrospinal fluid (CSF) levels of
markers of neural injury and immune activation have been found in HIV dementia, but neither of
those, nor CSF HIV-1 RNA levels have been proven useful as diagnostic or prognostic
pseudomarkers in HIV dementia.
Case presentation: We report a case of HIV dementia (MSK stage 3) in a 57 year old
antiretroviral naïve man who was introduced on zidovudine, lamivudine and ritonavir boosted
indinavir, and followed with consecutive lumbar punctures before and after two and 15 months
after initiation of HAART. Improvement of neurocognitive function was paralleled by normalisation
of CSF neural markers (NFL, Tau and GFAP) levels and a decline in CSF and serum neopterin and
CSF and plasma HIV-1 RNA levels.
Conclusion: The value of these CSF markers as prognostic pseudomarkers of the effect of
HAART on neurocognitive impairment in HIV dementia ought to be evaluated in longitudinal
studies.
Background
Neurological complications are common in HIV-1 infec-
tion and HIV-1 can be detected in cerebrospinal fluid
(CSF) or brain tissue in all stages of infection[1,2]. HIV
dementia, also termed HIV associated dementia or AIDS
dementia complex, is a subcortical dementia which is
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characterised by a combination of cognitive/behavioural
and motor dysfunction. The diagnosis is based on clinical
criteria and the absence of other diseases that may explain
the condition and requires a thorough clinical examina-
tion along with radiological imaging of the brain and CSF
analyses. About half of patients with HIV dementia have
neuropathological findings consistent with HIV-1
encephalitis, which is characterised by multinucleated
giant cells, microglial nodules, perivascular inflamma-
tion, astrocytosis, myelin pallor, and neuronal loss[3,4].
There seem to be regional differences in neuropathology
and viral load. Subcortical structures such as basal ganglia,
especially nucleus caudatus, and the hippocampus appear
to be most vulnerable[3,5].
The exact mechanisms of neuronal injury in HIV-1 infec-
tion are not known. However, as cells of macrophage/
microglial-lineage are the only productively infected cells
in the central nervous system (CNS) an indirect neuro-
toxic effect has been suggested [6-8]. Intrathecal immu-
noactivation is probably also part of the
neuropathogenicity and neurodegeneration is most often
accompanied by increased immunostimulation [9-11].
Neopterin is a marker of cellular immune activation and
is secreted by monocyte-derived macrophages when stim-
ulated by interferon gamma. High CSF neopterin levels
have been found in HIV-1 infected patients with HIV
dementia and CNS opportunistic disease[12,13]. Neuro-
filament is a major structural component of myelinated
axons. The light chain of the neurofilament protein (NFL)
can be used as a marker of CNS injury. Elevated CSF levels
of NFL have been found in cerebrovascular disease, mul-
tiple sclerosis, herpes simplex encephalitis, amyotrophic
lateral sclerosis, and AIDS[14,15]. Protein tau (Tau) is a
microtubuli associated protein that promotes microtubuli
assembly and stability. A hyperphosphorylated form of
Tau (Paired helical filaments (PHF)-Tau) is found in brain
tissue from patients with Alzheimer's disease. Elevated
levels of normal and PHF-Tau have been found in Alzhe-
imer's disease, vascular dementia, HIV dementia, and
HIV-1 infected patients with CNS opportunistic dis-
ease[9,16]. The glial fibrillary acidic protein (GFAP) is the
structural protein of the glial intermediate filament,
which constitutes the morphological basis of astrogliosis.
Increased CSF levels of GFAP have been demonstrated in
patients with Alzheimer's disease, vascular dementia,
multiple sclerosis, and AIDS[17,18]. Elevated CSF levels
of S-100 protein (S100), a marker of astroglial cell
destruction, and neuron specific enolase (NSE), a marker
of neural injury, have been found in herpes simplex
encephalitis[19]. Blood-brain barrier (BBB) impairment,
as measured by the albumin ratio, has been found in HIV-
1 infected patients in various stages of disease and the pro-
portion of HIV-1 infected individuals with an elevated
albumin ratio seems to increase with more advanced dis-
ease [20-22]. In fact, some groups have reported impaired
BBB integrity in 100% of patients with HIV-encephali-
tis[23,24]. IgG index is used as a measurement of intrath-
ecal antibody production. High IgG index values have
been found in HIV-1 infected patients with neurological
complications[25]. High CSF HIV-1 RNA levels have been
found in patients with HIV dementia but neither CSF HIV-
1 RNA levels nor markers of immune activation, neural
injury or BBB dysfunction have been proven useful as
prognostic or diagnostic markers in HIV dementia [26-
29].
CSF and serum neopterin were analysed by radio-immu-
noassay (Henningtest neopterin, Brahms, Berlin, Ger-
many), CSF NFL, Tau, and GFAP by previously described
enzyme linked immunoassays[14,16,17], and CSF and
plasma HIV-1 RNA by quantitative PCR (Roche UltraSen-
sitive HIV Monitor and Amplicor HIV Monitor version
1.5, Hoffman La-Roche, Basel, Switzerland). Samples
with HIV-1 RNA levels exceeding the upper limit of the
dynamic range of the UltraSensitive HIV Monitor test
(>75000 HIV-1 RNA copies/ml) were reanalysed with the
Amplicor HIV Monitor test (dynamic range 400–750000
HIV-1 RNA copies/ml).
Since the introduction HAART the incidence of HIV
dementia has declined[30,31]. Several groups have
reported improved neurocognitive function after initia-
tion of HAART, while others have found continued
decline in neurologic function in a subset of individuals
despite good virological control [32-34].
We report a case of HIV dementia in a patient who was fol-
lowed with repeated CSF sampling before and after initia-
tion of HAART and where neurocognitive improvement
was paralleled by declining levels of CSF markers of neu-
ral injury.
Case presentation
A 57 year old previously healthy man was admitted to the
Department of Infectious Diseases, Sahlgrenska Univer-
sity Hospital, Göteborg, Sweden in January 2000. He pre-
sented with a three month history of increasing apathy,
gait difficulties and memory dysfunction. On examina-
tion he showed normal vital signs. Neurological examina-
tion revealed ataxic gait, memory impairment, reduced
attention and slow verbal response. A HIV-1 antibody test
was positive and his CD4-cell count was 50 ×10e6 cells/l.
A brain MRI scan revealed no intracranial pathology
except for areas of increased signal changes in T2 MRI
sequences in periventricular white matter. Following MRI
scan a lumbar puncture and additional blood tests were
performed. Routine laboratory tests were normal except
for an elevated sedimentation rate (76 mm/h). Tests andBMC Infectious Diseases 2006, 6:141 http://www.biomedcentral.com/1471-2334/6/141
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cultures in CSF and blood for bacterial, mycobacterial,
fungal and protozoal infections, including PCR tests for
JC-virus, cytomegalovirus, herpes simplex virus, varicella
zoster virus, Epstein-Barr virus, and toxoplasmosis in CSF,
antigen test for cryptococci in CSF, and antibody test for
syphilis in CSF and blood, were negative. CSF PCR tests
for diagnostic purposes were run as soon as possible after
sampling. CSF cytology was normal. Thus, brain MRI scan
and CSF assessment showed no evidence of other infec-
tions or malignancies. CSF and plasma HIV-1 RNA levels,
CSF cell counts, and CD4 cell counts are presented in fig-
ure 1. After additional neurological and psychiatric tests,
performed by an experienced neurologist, a diagnosis of
HIV dementia (MSK stage 3)[35,36] was made. The
patient was introduced on zidovudine 300 mg BID, lami-
vudine 150 mg BID, indinavir 800 mg BID and ritonavir
100 mg BID p.o. in January 2000 and was then followed
with physical and neurological examination and CSF
assessment after 2 and 15 months. He showed a gradual
neurocognitive improvement that was paralleled by a
decline in plasma and CSF HIV-1 RNA levels as well as lev-
els of CSF NFL, Tau, GFAP, neopterin, TAU, albumin ratio,
and IgG index (figure 1). CSF levels of S-100 protein and
NSE were below the upper limit of normal before treat-
ment initiation. Neurological examination after 15
months of HAART showed no remaining neurocognitive
impairment and the patient had resumed all activities of
daily living, as well as full time work.
Discussion
Although the incidence of HIV dementia has declined
since the introduction of HAART[30,31], the effect of
HAART on HIV dementia has not been as thoroughly eval-
uated. Also, the long term effects of HAART on neurolog-
ical impairment in HIV-1 infection are not well known
and there have been reports of continued neurological
impairment in spite of virological control in some
patients with HIV dementia[33]. We have previously
found elevated CSF neopterin levels after 2 years of con-
tinuous HAART in neuroasymptomatic HIV-1 infected
patients[37] and recently reported increasing CSF levels of
Cerebrospinal fluid (CSF) and plasma HIV-1 RNA (log10 copies/ml), and CD4 cell count (cells/μl) Figure 1
Cerebrospinal fluid (CSF) and plasma HIV-1 RNA (log10 copies/ml), and CD4 cell count (cells/μl) (a); CSF NFL (* <250 ng/L), 
CSF Tau (* <400 ng/L), and CSF GFAP (*<750 ng/L) (b); CSF neopterin (* <4.2 nmol/L) and serum neopterin (* <8.8 nmol/L), 
and CSF mononuclear cell count (cells/μL) (c); albumin ratio (* <10.2) and IgG index (*<0.63) (d); before, and after two and 15 
months after initiation of HAART. *Upper limit of normal.
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NFL in a subset of neuroasymptomatic HIV-1 infected
patients after discontinuation of HAART[38].
In the case reported here, complete neurocognitive recov-
ery was paralleled by normalisation of CSF-levels of NFL
and HIV-1 RNA, indicating that the process of axonal
damage might have been halted by the CSF penetrating
combination of zidovudine, lamivudine, ritonavir and
indinavir. It seemed as if CSF NFL decrease was slow com-
pared to the decrease in CSF Tau and GFAP levels. Slow
CSF NFL normalisation has been reported in herpes sim-
plex type 1 encephalitis, focal brain ischemia, and multi-
ple sclerosis[19,39]. Whether this reflects slow metabolic
degradation and a long half-life of NFL in CSF or different
immunopathological pathways that lag behind the
decrease in HIV-1 replication in CNS is not clear. In our
patient CSF WBC and neopterin followed the same pat-
tern as CSF NFL indicating a correlation with intrathecal
immune activation. The decline in albumin ratio and IgG
index values was in concordance with previous reports on
effects of HAART on BBB integrity and intrathecal anti-
body production[40].
Before the introduction of HAART, two-thirds of patients
with HIV dementia followed a rapid course with fast dete-
rioration and death while the other third had a slower
clinical course with prolonged survival[41]. In recent
reports it seems that some patients with HIV dementia
experience rapid neurocognitive improvement while oth-
ers have a less pronounced or no effect after starting
HAART [32-34]. If this is explained by different mecha-
nisms of neural injury or if some patients develop irrevers-
ible brain damage prior to treatment is not known.
Conclusion
Rapid decline in CSF markers of axonal damage, as
described here, indicates that CSF NFL, or a combination
of markers of neural injury, might be of value as an indi-
cator of the effect of HAART on neurocognitive impair-
ment in patients with HIV dementia and merits
evaluation as a prognostic pseudomarker in treatment of
HIV dementia in longitudinal studies.
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